Jean Pineault
Director Ejecutivo en Biohybrid Solutions Holding, Inc. .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Krzysztof Matyjaszewski | M | - |
Biohybrid Solutions Holding, Inc.
Biohybrid Solutions Holding, Inc. BiotechnologyHealth Technology Biohybrid Solutions Holding, Inc. is a company that focuses on delivering safe and effective biologic drugs to patients worldwide. The company has partnered with the US government on a $38m DTRA program, which includes the discovery, manufacturing, testing, and scale-up of nanoarmored™ drugs. The company is based in Sharpsburg, PA. The company's world-renowned scientists are spearheading innovations in protein therapeutics by solving a problem facing the pharmaceutical industry: how to create longer-lived, more effective medicine. The company has developed the immunocontrol ™ platform, which can be used for epitopetargeting ™ and epitopeaccentuation ™, allowing for the discovery of new drugs against secondary, silent epitopes. The company has also modified cancer-fighting mini-proteins to increase pharmacokinetics. Biohybrid Solutions Holding was founded in 2016 by Antonina Simakova, Alan Russell, and Krzysztof Matyjaszewski. Jean Pineault has been the CEO of the company since 2021. | - |
Alan Russell | M | - |
Biohybrid Solutions Holding, Inc.
Biohybrid Solutions Holding, Inc. BiotechnologyHealth Technology Biohybrid Solutions Holding, Inc. is a company that focuses on delivering safe and effective biologic drugs to patients worldwide. The company has partnered with the US government on a $38m DTRA program, which includes the discovery, manufacturing, testing, and scale-up of nanoarmored™ drugs. The company is based in Sharpsburg, PA. The company's world-renowned scientists are spearheading innovations in protein therapeutics by solving a problem facing the pharmaceutical industry: how to create longer-lived, more effective medicine. The company has developed the immunocontrol ™ platform, which can be used for epitopetargeting ™ and epitopeaccentuation ™, allowing for the discovery of new drugs against secondary, silent epitopes. The company has also modified cancer-fighting mini-proteins to increase pharmacokinetics. Biohybrid Solutions Holding was founded in 2016 by Antonina Simakova, Alan Russell, and Krzysztof Matyjaszewski. Jean Pineault has been the CEO of the company since 2021. | 8 años |
Antonina Simakova | M | - |
Biohybrid Solutions Holding, Inc.
Biohybrid Solutions Holding, Inc. BiotechnologyHealth Technology Biohybrid Solutions Holding, Inc. is a company that focuses on delivering safe and effective biologic drugs to patients worldwide. The company has partnered with the US government on a $38m DTRA program, which includes the discovery, manufacturing, testing, and scale-up of nanoarmored™ drugs. The company is based in Sharpsburg, PA. The company's world-renowned scientists are spearheading innovations in protein therapeutics by solving a problem facing the pharmaceutical industry: how to create longer-lived, more effective medicine. The company has developed the immunocontrol ™ platform, which can be used for epitopetargeting ™ and epitopeaccentuation ™, allowing for the discovery of new drugs against secondary, silent epitopes. The company has also modified cancer-fighting mini-proteins to increase pharmacokinetics. Biohybrid Solutions Holding was founded in 2016 by Antonina Simakova, Alan Russell, and Krzysztof Matyjaszewski. Jean Pineault has been the CEO of the company since 2021. | 8 años |
Mark Murcko | M | 64 |
Biohybrid Solutions Holding, Inc.
Biohybrid Solutions Holding, Inc. BiotechnologyHealth Technology Biohybrid Solutions Holding, Inc. is a company that focuses on delivering safe and effective biologic drugs to patients worldwide. The company has partnered with the US government on a $38m DTRA program, which includes the discovery, manufacturing, testing, and scale-up of nanoarmored™ drugs. The company is based in Sharpsburg, PA. The company's world-renowned scientists are spearheading innovations in protein therapeutics by solving a problem facing the pharmaceutical industry: how to create longer-lived, more effective medicine. The company has developed the immunocontrol ™ platform, which can be used for epitopetargeting ™ and epitopeaccentuation ™, allowing for the discovery of new drugs against secondary, silent epitopes. The company has also modified cancer-fighting mini-proteins to increase pharmacokinetics. Biohybrid Solutions Holding was founded in 2016 by Antonina Simakova, Alan Russell, and Krzysztof Matyjaszewski. Jean Pineault has been the CEO of the company since 2021. | 2 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Jacques Lemieux | M | - |
University of Ottawa
| 3 años |
Christophe J. Echeverri | M | - |
University of Ottawa
| 6 años |
Christopher C. Miller | M | - |
University of Ottawa
| 4 años |
Mei Jie Zhang | M | 60 |
University of Ottawa
| 3 años |
Samir Khan | M | - |
University of Ottawa
| 4 años |
Mike Morency | M | - |
University of Ottawa
| 3 años |
Karim Lalani | M | 58 |
University of Ottawa
| 3 años |
Jean-Michel Lemieux | M | - |
University of Ottawa
| 4 años |
Andrew Chuk | M | 66 |
University of Ottawa
| 3 años |
Robert Andre Seguin | M | - |
University of Ottawa
| 4 años |
Martin Bélanger | M | - |
University of Ottawa
| 4 años |
Duane William Green | M | - |
University of Ottawa
| 3 años |
Eric Paul-Hus | M | - |
University of Ottawa
| 3 años |
Stephen Partridge | M | - |
University of Ottawa
| 6 años |
Loon Chun Yang | M | 77 |
University of Ottawa
| 3 años |
Meena Ballantyne | F | - |
University of Ottawa
| 1 años |
Denis Zaccarin | M | 59 |
University of Ottawa
| 3 años |
Diane Lafontaine | F | - |
University of Ottawa
| 2 años |
Terrence Connolly | M | - |
University of Ottawa
| 5 años |
Raj Kumar | M | 55 |
University of Ottawa
| 4 años |
David Roy | M | - |
University of Ottawa
| 4 años |
Pik Sing Choi | M | - |
University of Ottawa
| 4 años |
Marco Bastidas | M | 59 |
University of Ottawa
| 4 años |
Ken Klassen | M | 58 |
University of Ottawa
| 3 años |
Peter Holst | M | 56 |
University of Ottawa
| 4 años |
Mark Deriet | M | - |
University of Ottawa
| 4 años |
Vincent Lépine | M | - |
University of Ottawa
| 1 años |
Doug Reid | M | - |
University of Ottawa
| 4 años |
Walter Spracklin | M | - |
University of Ottawa
| 4 años |
Marc Tellier | M | 55 |
University of Ottawa
| 4 años |
Scott Wilson | M | - |
University of Ottawa
| 4 años |
Elizabeth Douville | M | - |
University of Ottawa
| 3 años |
Perry Dellelce | M | - |
University of Ottawa
| 3 años |
Terry Connolly | F | - |
University of Ottawa
| 5 años |
Carl Pelland | M | - |
University of Ottawa
| 4 años |
James Lavigne | M | 60 |
University of Ottawa
| 1 años |
Richard Jonathan Fortin | M | - |
University of Ottawa
| 4 años |
Carlos Manuel Yuste | M | - |
University of Ottawa
| 4 años |
Francisco Diaz-Mitoma | M | 69 |
University of Ottawa
| 21 años |
Geneviève Lavallée | F | - |
University of Ottawa
| 5 años |
Irvine R. Annesley | M | - |
University of Ottawa
| 3 años |
Prashant R. Watchmaker | M | - |
University of Ottawa
| 4 años |
Paul N. Hughes | M | - |
University of Ottawa
| 4 años |
Bobbi Faulkner | F | - |
University of Ottawa
| 4 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Canadá | 44 | 91.67% |
Estados Unidos | 4 | 8.33% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Jean Pineault
- Red Personal